Genomic analyses of tissues from mantle cell lymphoma patients helped researchers explain two types of drug resistance and ways to overcome them in the clinic.
A phase III trial of Nexavar tablets in patients with advanced breast cancer did not meet its primary endpoint of extending progression-free survival.
Researchers with The Cancer Genome Atlas Network found that stomach cancers fall into four distinct molecular subtypes.
A phase III trial of Arzerra as a maintenance therapy for chronic lymphocytic leukemia met its primary endpoint of extending progression-free survival at an interim analysis.
A German company that makes devices now under FDA scrutiny for their potential to spread sarcoma threatened legal action against the U.S. surgeon whose wife's cancer cells were disseminated during routine surgery to remove fibroids.
Emmanuel Farber, a pathologist who made contributions to the understanding of chemical carcinogenesis, died Sunday, Aug. 3.
Ethicon, the Johnson & Johnson subsidiary that manufactures nearly three-quarters of laparoscopic power morcellators on the market, has requested a withdrawal of the controversial devices.
FDA approved Zydelig (idelalisib) tablets for the treatment of three B-cell blood cancers.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
